Related Experiment Videos
The effects of captopril in severe congestive heart failure. An echocardiographic study
S I Drăgulescu1, M Nicolin, C Streian
1Department of Cardiology, County Timişoara Hospital, Romania.
Insights
Captopril treatment significantly improved heart function in patients with severe congestive heart failure (CHF). This ACE inhibitor reduced heart size and improved ejection fraction, relieving symptoms like dyspnea and fatigue.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Severe congestive heart failure (CHF) presents significant challenges in patient management.
- Existing treatments often have limitations in improving cardiac function and patient symptoms.
Purpose of the Study:
- To evaluate the efficacy of captopril in patients with severe chronic congestive heart failure.
- To assess the impact of captopril on left ventricular dimensions, ejection fraction, and clinical symptoms.
Main Methods:
- A study involving 12 patients with severe CHF.
- Captopril was administered at doses of 25-150 mg every 8 hours for 2 months, alongside standard cardiac glycoside and diuretic therapy.
- Echocardiographic parameters including left ventricular end-diastolic diameter (EDD) and end-systolic diameter (ESD), ejection fraction (EF), and mean velocity of circumferential fiber shortening (Vcf) were measured.
Main Results:
- Significant reductions in left ventricular end-diastolic diameter (p<0.05) and end-systolic diameter (p<0.001) were observed.
- Ejection fraction (p<0.005) and mean velocity of circumferential fiber shortening (p<0.001) showed significant increases.
- Patients experienced marked relief from dyspnea and fatigue, with functional class improvements.
Conclusions:
- Captopril demonstrates effectiveness in improving cardiac function and reducing symptoms in severe chronic congestive heart failure.
- The findings suggest captopril as a valuable therapeutic option for managing severe CHF.
- Further research can explore long-term effects and optimal dosing strategies.
Abstract:
In 12 patients with severe congestive heart failure (CHF), captopril in doses of 25 to 150 mg, every 8 hours, was given for a period of 2 months, in addition to cardiac glycoside and diuretic drugs. After this treatment left ventricular end-diastolic diameter (EDD) decreased from 6.4 +/- 0.5 to 6.2 +/- 0.6 cm (p less than 0.05), left-ventricular end-systolic diameter (ESD) decreased from 5.7 +/- 0.5 to 5.4 +/- 0.6 cm (p less than 0.001), the ejection fraction increased from 30.8 +/- 7.0 to 36.2 +/- 6.9% (p less than 0.005) and mean velocity of circumferential fiber shortening (Vcf) increased from 0.51 +/- 0.12 to 0.62 +/- 0.13 circ/sec (p less than 0.001). Captopril markedly relieved dyspnea and fatigue. Three patients improved from class IV to class III, 4 patients from class IV to class II and 3 patients from class III to class II. These data suggest that captopril may be effective in the treatment of severe chronic CHF.